Table 1.

Baseline Characteristics of the Treatment Arms

Characteristic	Donepezil (N = 7)	Placebo (N = 9)
Participant Age (Mean ± STD, yrs)	88.0 ± 5.2	87.0 ± 3.7
Participant Gender – Female N(%)	5 (71%)	4 (44%)
Participant Race
Black N(%)	1 (14%)	1 (11%)
White N(%)	6 (86%)	8 (89%)
Participant H/O Dementia
Yes N(%)	3 (43%)	4 (44%)
No N(%)	4 (57%)	5 (56%)
Pre-fracture ADL Score
(Mean ± STD)	13.3 ± 3.6	12.8 ± 4.7
(0– 16, 16 best)
Participant Education
< High School N(%)	0	0
High School N(%)	1 (14%)	3 (33%)
Some College N(%)	2 (29%)	2 (22%)
Associate Degree N(%)	1 (15%)	0
Bacc Degree N(%)	1 (14%)	1 (11%)
Masters N(%)	1 (17%)	1 (11%)
Doctoral N(%)	0	1 (11%)
Unknown N(%)	0	1 (11%)
Anticholinergic Drug Exposure
Preoperative	1 (14%)	0
Postoperative	7 (100%)	7 (78%)
Neuroleptic Drug Exposure
Preoperative	2 (29%)	1 (11%)
Postoperative	3 (43%)	4 (44%)

Per the CONSORT recommendations for the reporting of clinical trials (24), no p-values are included in this table.